Hydrix Ltd (ASX:HYD)'s Gavin Coote gives Proactive a rundown of the company's product development arm. With a universal vision to "improve a billion lives" with its medtech innovations, Hydrix is preparing for commercial product launches in the cardiovascular disease market in 2022. The company's flagship solutions include the AngelMed Guardian, an implantable monitoring device awaiting Therapeutic Goods Administration (TGA) approval, and the Phyzhon FFR, a cardiovascular surgery device.
Hydrix out to "improve a billion lives" with cardiovascular medtech offerings
